The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.
The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.
Recruiting · NCT06330012 · Registry updated 2024-03-26Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients. | HER2-positive Breast Cancer | Recruiting | Not applicable | 2024-03-26 | NCT06330012 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Samsung Medical Center | 207 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Ji-Yeon Kim | Seoul | South Korea | 4 |